Sana Biotechnology (NASDAQ:SANA) Issues Quarterly Earnings Results

Sana Biotechnology (NASDAQ:SANA) posted its quarterly earnings results on Thursday. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01, FiscalAI reports.

Sana Biotechnology Stock Performance

Shares of SANA traded up $0.03 during midday trading on Friday, hitting $2.37. 2,288,443 shares of the stock were exchanged, compared to its average volume of 2,997,985. The firm has a market cap of $709.48 million, a P/E ratio of -4.47 and a beta of 2.30. Sana Biotechnology has a 52-week low of $2.22 and a 52-week high of $5.49. The stock has a fifty day simple moving average of $2.88 and a 200 day simple moving average of $3.35.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on SANA shares. TD Cowen upgraded Sana Biotechnology to a “strong-buy” rating in a research report on Monday, August 24th. Bank of America lowered their target price on shares of Sana Biotechnology from $7.00 to $6.00 and set a “buy” rating for the company in a research note on Friday, August 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Sana Biotechnology in a research note on Wednesday, October 21st. Finally, Wall Street Zen cut shares of Sana Biotechnology from a “hold” rating to a “sell” rating in a report on Monday, July 20th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Sana Biotechnology currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.60.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc is a clinical-stage biotechnology company focused on developing engineered cell and gene therapies for serious diseases. The company’s approach is designed to create durable treatments by modifying cells outside or inside the body and using them to replace, repair, or supplement damaged or missing biological functions.

Sana is developing proprietary technologies intended to support the delivery and persistence of therapeutic cells. These include platforms for engineering cells to evade immune-system detection, potentially allowing donor-derived cells to be used without extensive immune suppression, as well as methods for delivering genetic instructions directly to targeted tissues.